Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01569191
Other study ID # Allergy12
Secondary ID
Status Completed
Phase Phase 4
First received March 27, 2012
Last updated July 24, 2017
Start date March 2012
Est. completion date February 2013

Study information

Verified date July 2015
Source Aston University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC.


Description:

There will be a total of 6 study visits, each lasting approximately 1 hour and separated by at least 2 days. At the beginning of each visit, a set of measurements will be taken by an experienced optometrist. These are:

- What symptoms you are feeling and how severe they are - you will be asked to complete a short questionnaire about how your eyes currently feel.

- The redness and temperature of your eyes - the front surface of both eyes will be photographed using digital cameras.

After these measurements we will ask you to stand inside a specially designed room where the environment can be controlled by a computer. The pollen that you were found to be allergic to will then be introduced into the atmosphere of the room, so that the signs and symptoms of SAC can be induced - this is intentional, but normally resolves within a few hours with no treatment. At each visit, you will experience a different duration (no longer than 10 minutes) and either no treatment, artificial tear supplement (ATS; preservative free ocular lubricant), cold compress (CC; cooled gel eye mask) or anti-allergic medication (epinastine hydrochloride 500μg/mL). The measurements will then be repeated even 5 minutes for an hour.

After the final set of measurements, the front surface of your eyes will be assessed using a temporary dye to highlight using a blue light any changes. Fluorescein dye does not sting, lasts only a few minutes and has no effect on vision or driving. However it may cause a self limiting mild allergic reaction where the eyes become red, irritated and sore but this is highly unlikely as there are no known reported cases. In the unlikely event this does happen the experienced optometrist is immediately available to manage the condition.

The anti-allergic drug epinastine hydrochloride (Elestat, Allergan) is a prescription only medicine indicated for the treatment of allergic conjunctivitis. As with all medications, there are potential side effects - although uncommon (1 in 10 to 1 in 100 people), there may be a slight burning sensation on application but this temporary and subsides quickly. The epinastine formulation also contains preservatives called benzalkonium chloride and disodium edetate. As with fluorescein sodium, these may cause a self limiting mild allergic reaction. In the unlikely event this does happen the experienced optometrist is immediately available to manage the condition.

Study Length and Reimbursement Each of the 6 measurement visits is separated by 7 days therefore the total study length for each participant is 6 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date February 2013
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- history of seasonal allergic conjunctivitis or seasonal allergic rhinoconjunctivitis (seasonal hay fever) that is not currently active.

Exclusion Criteria:

- eye surgery in the last 3 months

- active eye condition

- adverse reaction to ocular drugs or dyes

- history of anaphylaxis (severe systemic allergic reaction)

- use any ocular medication or systemic medications (antihistamines, mast cell stabilisers, non-steroidal anti-inflammatory drugs or steroids) at least 14 days prior to the start and for the duration of the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Artificial Tear Supplement
artificial tear supplement (Hypromellose)
Device:
Cold compress
Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
Drug:
Anti-allergic Medication
1 drop on single occasion after exposure to grass pollen

Locations

Country Name City State
United Kingdom National Pollen and Aerobiology Unit Worcester

Sponsors (2)

Lead Sponsor Collaborator
Aston University University of Worcester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptoms Short questionnaire Ocular allergy symptomology was also measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, swelling and soreness resulting in a summed score between 0 and 24. A higher score indicates a worse outcome (more severe symptoms) 1 hour
Primary Ocular Redness Bulbar and limbal redness will be observed with a slit lamp biomicroscope and graded using a validated scale
• The 'Efron' grading scale consists of 5 pictures of eyes of increasing severity of blood vessels over the white of the eye, with the clinician selecting the image closest to what they observe on the patient (0 indicating a white eye and 4 a very irritated eye). There are no subscales
1 hour
Primary Ocular Temperature Ocular surface temperature will be measured with an infra-red camera 1 hour
See also
  Status Clinical Trial Phase
Completed NCT04531540 - Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test) Phase 3
Completed NCT00988065 - Sugammadex Hypersensitivity Study (Study P06042) Phase 1
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02588326 - Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays Phase 1
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT02360072 - Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Completed NCT01494649 - Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity N/A
Enrolling by invitation NCT05039229 - Measures for Bioaerosol Reduction in the Salmon Industry N/A
Enrolling by invitation NCT05675241 - Characterizing the Inflammation Around Dental Implants
Completed NCT04006106 - Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
Completed NCT04605471 - A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Terminated NCT05247567 - Quaternary Ammonium and Immunization in Hairdressers N/A
Completed NCT05119751 - Vestibular Versus Sublingual Route of AIT Tablets Phase 4
Recruiting NCT06065137 - Standardised Drug Provocation Testing in Perioperative Hypersensitivity N/A
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Not yet recruiting NCT04485299 - Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient Phase 2/Phase 3
Completed NCT02686827 - DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. Phase 2